Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).
JOURNAL OF CLINICAL ONCOLOGY（2022）
关键词
continuous talazoparib,small cell lung cancer,cell lung cancer,lung cancer,low-dose,extensive-stage,es-sclc
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要